๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mumbai
Clinical trial register · India

Clinical Trials in Mumbai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1132 matching records held by the registry are in this view. Synced 27 Sep 2026, 03:16 UTC
1132
Studies in scope
all four open statuses
613
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
New Delhi 335 Mumbai 261 Hyderabad 238 Bangalore 199 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca36 Tata Memorial Centre33 Tata Memorial Hospital22 Novo Nordisk A/S12 Eli Lilly and Company11
Site location
New Delhi335 Mumbai261 Hyderabad238 Bangalore199 Pune189
All 275 locations
Target enrolment
to

Trials with a site in Mumbai

261 of 1132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
NCT07668401Obesity, Overweight
DrugZenagamtide
Novo Nordisk A/S
Phase 3
400
Surat, Vadodara, Hubbali, Kozhikode, Indore, Kohlapur, Kolhฤpur, Mumbai
2027-01-07
Not yet open
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
NCT07459543Unresectable Melanoma, Metastatic Melanoma
DrugsRelatlimab·Nivolumab
Bristol-Myers Squibb
Phase 4
40
Nashik, Mumbai, Navi Mumbai, Pune, Bhubaneswar, Chennai, Nagpur, New Delhi
2026-11-15
Not yet open
Tracheostomy Practice in Adult Intensive Care Units
NCT07769021Tracheostomy Patients, Tracheostomy Decannulation, Intensive Care (ICU)
Royal College of Surgeons, Ireland
Observational
2,500
Mumbai
2026-11-02
Not yet open
A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes
NCT07839338Major Depressive Episode
DrugsKetamine·Midazolam
Jawaharlal Institute of Postgraduate Medical Education & Research
Phase 3
220
Bangalore, Udupi, Mumbai, Bhubaneswar, Puducherry
2026-10
Not yet open
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
NCT07838155Alzheimer Disease
DrugDonanemab
Eli Lilly and Company
Phase 4
50
Bangalore, Kolkata, Mumbai, New Delhi, Tamil Nadu, Vellore
2026-10
Not yet open
The Primary Prevention of Intimate Partner Violence
NCT06811922Intimate Partner Violence
Emory University
Not applicable
1,700
Mumbai, Pune
2026-10
Not yet open
A Study of Chlorophyllin or Placebo With Standard Treatment for Late Radiation Induced Luminal Gastrointestinal Tract Bleeding
NCT07837713Radiation Proctitis, Gastrointestinal Hemorrhage, Radiation Injuries
DrugChlorophyllin, Sodium Copper Complex
Tata Memorial Centre
Phase 3
200
Mumbai
2026-09-15
Not yet open
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336Diabetes Mellitus, Type 2
DrugsDulaglutide·Orforglipron
Eli Lilly and Company
Phase 3
170
Ahmedabad, Aligarh, Bhubaneswar, Guntur, Mumbai, Nashik, New Delhi
2026-09
Not yet open
A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs
NCT07838753Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer
Kokilaben Dheerubhai Ambani Hospital and Research
Phase 2
170
Mumbai
2026-09
Recruiting
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
NCT06492486Diffuse Glioma, Glioblastoma, Adaptive Radiotherapy, Artificial Intelligence
Tata Memorial Centre
Phase 2
60
Mumbai
2026-07-27
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
NCT07613307Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders
DrugOrforglipron
Eli Lilly and Company
Phase 3
130
Agra, Hyderabad, Kanpur, Kolkata, Mumbai, Mysore, Nashik, Nellore
2026-07-15
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Guntur, Surat, Vadodara, Bangalore, Bengaluru, Kochi, Indore, Mumbai
2026-05-20
Recruiting
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
NCT06948214Growth Hormone Deficiency (GHD)
DrugLUM-201
Lumos Pharma
Phase 3
150
Mumbai, Nashik, Jaipur, Madurai, Chandigarh
2026-05-20
Recruiting
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Guntur, Vijayawada, Bengaluru, Kochi, Mumbai, Nagpur, Delhi, Bhubaneswar
2026-05-05
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Guntur, Vijayawada, Bengaluru, Kochi, Mumbai, Nagpur, New Delhi, Delhi
2026-05-05
Recruiting
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
NCT07555392Active Immunisation for Chikungunya Virus Infection
Bharat Biotech International Limited
Phase 2/3
1,000
Guwahati, Patna, Raipur, Mumbai, Rohtak, Bhubaneswar, Ajmer, Bikaner
2026-04-20
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Allahฤbฤd, Belagavi, Belgavi, Hyderabad, Jaipur, Kochi, Lucknow, Mumbai
2026-03-26
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Eluru, Goraj, Pลซlakkลd, Aurangabad, Mumbai, Nagpur, Dwarka, New Delhi
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
DrugsPumitamig·Folfox·Nivolumab
Bristol-Myers Squibb
Phase 2/3
690
Nashik, Mumbai, Delhi, Puducherry, Pune
2026-03-13
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 โ‰ฅ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Eluru, Visakhapatnam, Goraj, Mumbai, Nagpur, Dwarka, Hyderabad, Delhi
2026-03-12
Recruiting
Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors
NCT07404176Neuroendocrine Neoplasms (Tumours), Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors
Tata Memorial Hospital
Phase 2
20
Mumbai, Navi Mumbai
2026-03-01
Active, closed
Study to Assess the Efficacy of EMC-CAP-2025A on Age-Related Skin Parameters in Healthy Individuals
NCT07493850Facial Wrinkles, Skin Hydration, Skin Elasticity
Circul'Egg
Phase 2
60
Mumbai
2026-02-27
Recruiting
Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors
NCT07236840CNS Tumor, Artificial Intelligence (AI), Glioma, Digital Health
Tata Memorial Centre
Observational
600
Mumbai
2026-02-20
Recruiting
Asian Gynecological Brachytherapy Registry in Cervical Cancer
NCT07196033Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018, Stage IB Cervical Cancer FIGO 2018
Tata Memorial Hospital
Observational
1,000
Mumbai
2026-02-20
Not yet open
Affordable Made-in-India Microspheres for Liver Cancer Therapy
NCT07436988Hepatecellular Carcinoma
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 1
18
Chandigarh, Mumbai, Bhubaneswar, Puducherry, Delhi
2026-02-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Guntur, Guwahati, Hyderabad, Mandya, Mumbai, Mysore, Nagpur, Nashik
2026-02-06
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin
AstraZeneca
Phase 3
2,130
Ahmedabad, Bhubaneswar, Hyderabad, Kolkata, Mohali, Mumbai, New Delhi, Varanasi
2026-02-03
Recruiting
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
NCT07184619Treatment-resistant Schizophrenia
Newron Pharmaceuticals SPA
Phase 3
400
Vijayawada, Guwahati, Mumbai, Nagpur, Navi Mumbai, Madurai, Bฤซbฤซnagar, Lucknow
2026-01-23
Recruiting
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
NCT07282743Type II Diabetes Mellitus
DrugGL0034
Sun Pharmaceutical Industries Limited
Phase 2
285
Guntur, Bangalore, Kozhikode, Trivandrum, Kolhฤpur, Mumbai, Pune, New Delhi
2026-01-20
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsBMS-986504·Nab-paclitaxel·Pemetrexed·Paclitaxel
Bristol-Myers Squibb
Phase 2/3
590
Bangalore, Bengaluru, Mumbai, Nashik, New Delhi, Varanasi, Hyderabad
2026-01-02
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Pumitamig·Folfox·Bevacizumab
Bristol-Myers Squibb
Phase 2/3
990
Nashik, Thiruvananthapuram, Mumbai, Delhi, Puducherry, Pune
2025-12-31
Recruiting
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT07285460Hemophilia
DrugsAntithrombin·Clotting factor concentrates·Fitusiran
Sanofi
Phase 3
85
Bengaluru, Mumbai, Pune, Vellore
2025-12-18
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Delhi, Hyderabad, Kolhฤpur, Kolkata, Mumbai, Nashik, Surat
2025-12-04
Recruiting
BIO-SHORT: Hypofractionated RT for Poor-Prognosis GBM
NCT07338539Glioma
Tata Memorial Centre
Not applicable
108
Mumbai
2025-11-06
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
Ahmedabad, Gurugram, Bengaluru, Mumbai, Nagpur, New Delhi, Howrah
2025-11-05
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDatopotamab Deruxtecan·Docetaxel
AstraZeneca
Phase 3
400
Bangalore, Kolkata, Mumbai, Nashik, New Delhi
2025-10-31
Recruiting
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
NCT06804135Cervical Carcinoma
Tata Memorial Hospital
Observational
110
Mumbai
2025-10-25
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
Kochi, Mumbai, New Delhi, Bhubaneswar, Hyderabad, Varanasi, Kolkata
2025-10-23
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
DrugPonsegromab
Pfizer
Phase 2/3
982
Mumbai, New Delhi, Jaipur, Kolkata
2025-10-03
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628Acute Coronary Syndrome
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
300
Belagavi, Mumbai, Nashik, Bikaner
2025-10-03
Recruiting
Phase II Trial of Immunonutrition in Hepatectomy
NCT07395635Hepatocellular Carcinoma, ASA I-III Patients
Tata Memorial Centre
Not applicable
100
Mumbai
2025-10-03
Recruiting
Data Collection Using Eko Devices in a Clinical Setting
NCT07270744Lung Diseases
Eko Devices, Inc.
Observational
200
Mumbai
2025-10-01
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
DrugsPF-08046054·Docetaxel
Pfizer
Phase 3
680
Mumbai, Pune, New Delhi, Kolkata, Delhi, Kerala
2025-09-29
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Mumbai, Nagpur, New Delhi, Chennai, Hyderabad, Varanasi
2025-09-11
Recruiting
A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India
NCT07157423Severe Postpartum Haemorrhage
DrugRecombinant Factor VIIa
Novo Nordisk A/S
Phase 4
64
Belagavi, Mysore, Kozhikode, Mumbai, New Delhi, Jaipur, Udaipur, Hyderabad
2025-08-26
Recruiting
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
NCT07042100Advanced Solid Tumors
DrugPumitamig
Sun Pharma Advanced Research Company Limited
Phase 1
177
Rohtak, Ernฤkulam, Mumbai, Pune, Delhi, Bikaner, Udaipur
2025-08-12
Recruiting
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
NCT07141004Arthritis, Psoriatic
DrugGuselkumab
Johnson & Johnson Private Limited
Phase 4
100
Ahmedabad, Chandigarh, Chennai, Gorakhpur, Hyderabad, Mumbai, New Delhi, Patna
2025-08-12
Recruiting
Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT)
NCT07338526Brain Tumor, Pediatric
Tata Memorial Centre
Not applicable
94
Mumbai
2025-08-07
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
Belagavi, Delhi, Hyderabad, Kolkata, Mumbai
2025-08-07
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Ansฤrinagar, Babgalore, Calicut, Delhi, Hyderabad, Kannur, Kanpur, Mumbai
2025-08-06
Recruiting
Detection of Reduced Left Ventricular Ejection Fraction With Three-Lead ECG Using Artificial Intelligence
NCT07270692Low Ejection Fraction
Eko Devices, Inc.
Observational
500
Mumbai
2025-08-01
Active, closed
Effects of a Financial Literacy and Gender-Transformative Couples Intervention on Parenting Practices in India
NCT07651670Parenting Practices, Intimate Partner Violence (IPV), Mental Health, Empowerment
Shruti Shukla
Not applicable
4,552
Visakhapatnam, Mumbai, Jaipur, Noida
2025-07-29
Recruiting
Strengthening Relationships and Mental Health Through a Couples-Based Economic Empowerment Intervention
NCT07108049Mental Health, Empathy, Relation, Interpersonal
Technical University of Munich
Not applicable
4,500
Mumbai, Noida
2025-07-29
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine
Celgene
Phase 3
400
Bengaluru, Mumbai, New Delhi, Hyderabad
2025-07-28
Recruiting
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
NCT07044687Acute Myeloid Leukemia
DrugsAzacitidine·Venetoclax
AbbVie
Phase 4
100
Gurgaon, Bengaluru, Thiruvananthapuram, Mumbai, Pune, New Delhi, Bhubaneswar, Chennai
2025-07-24
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsSigvotatug vedotin·Pembrolizumab
Pfizer
Phase 3
714
Bengaluru, Mumbai, Pune, Thane, New Delhi, Hyderabad
2025-07-23
Recruiting
Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors
NCT06831461Primary Brain Tumors, Diffuse Glioma, Meningioma, Pituitary Adenoma
Tata Memorial Centre
Not applicable
156
Mumbai
2025-07-01
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
DrugsAAA817·ARPI
Novartis Pharmaceuticals
Phase 3
940
Gurgaon, Bengaluru, Mumbai
2025-07-01
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Vadodara, Kochi, Mumbai, Nagpur, New Delhi, New Dehli, Ludhiana, Dehradun
2025-06-30
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Belagavi, Coimbatore, Dehradun, Delhi, Dwฤrka, Hyderabad, Kochi, Mumbai
2025-06-27
Recruiting
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
NCT06862219Metastatic Urothelial Carcinoma
DrugEnfortumab Vedotin
Astellas Pharma Global Development, Inc.
Phase 4
100
Patna, Kochi, Mumbai, New Delhi, Dumas, Vellore, Varanasi, Kolkata
2025-06-21
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugsBemnifosbuvir-Ruzasvir·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Hyderabad, Patna, Rajkot, Surat, Shimla, Belagavi, Kochi, Mumbai
2025-06-02
Active, closed
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
NCT07030517Multiple Myeloma
DrugTeclistamab
Johnson & Johnson Private Limited
Phase 4
75
Bangalore, Bengaluru, Chandigarh, Jaipur, Kolkata, Mumbai, Nagpur, New Delhi
2025-05-22
Recruiting
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
NCT06703606Severe Hemophilia A
DrugMarstacimab
Pfizer
Phase 1
15
Surat, Mumbai
2025-05-13
Recruiting
Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study
NCT07435623Endometrial Cancer, Cervix Cancer
Tata Memorial Hospital
Observational
300
Mumbai
2025-05-10
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Hyderabad, Raipur, Ahmedabad, Nadiฤd, Bangalore, Kozhikode, Trivandrum, Mumbai
2025-05-08
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Ahmedabad, Ernฤkulam, Mumbai, New Delhi, Ludhiana, Vellore, Ghaziabad, Kolkata
2025-05-06
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab
AstraZeneca
Phase 3
1,220
Ahmedabad, Bangalore, Binnฤguri, Dehradun, Delhi, Hyderabad, Mumbai, Nashik
2025-05-06
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Visakhapatnam, Ahmedabad, Thiruvananthapuram, Mumbai, New Delhi, Bhubaneswar, Madurai, Hyderabad
2025-04-24
Active, closed
A Clinical Study to Evaluate the Efficacy of Native CT-IIยฎ in Individuals With Knee Osteoarthritis
NCT06917287Knee Osteoarthritis (OA)
Vedic Lifesciences Pvt. Ltd.
Not applicable
114
Mumbai, Nashik, Panvel
2025-04-20
Recruiting
Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative
NCT05774483Mouth Neoplasms, Oral Cancers, Oral Squamous Cell Carcinoma (OSCC), Oral Squamous Cell Carcinomas
Tata Memorial Hospital
Not applicable
508
Mumbai, Navi Mumbai, Varanasi
2025-04-16
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Ahmedabad, Aurangabad, Chennai, Mumbai, Namakkal, Patna, Pune, Thalassery
2025-03-27
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
Ahmedabad, Kolkata, Mumbai, Nagpur, Nashik, Pune, Vadodara, Varanasi
2025-03-19
Recruiting
IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer
NCT06630793Malignant Neoplasm of Anal Canal
Tata Memorial Centre
Not applicable
108
Mumbai
2025-03-18
Recruiting
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Ulcerative Colitis on Advanced Therapies
NCT06906445Ulcerative Colitis
All India Institute of Medical Sciences
Not applicable
220
Kochi, Mumbai, New Delhi, Ludhiana, Chandigarh, Varanasi
2025-03-15
Recruiting
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Ulcerative Colitis
NCT06895252Ulcerative Colitis (UC)
All India Institute of Medical Sciences
Not applicable
220
Kochi, Mumbai, New Delhi, Ludhiana, Chandigarh, Varanasi
2025-03-15
Recruiting
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Crohn Disease
NCT06890650Crohn Disease
All India Institute of Medical Sciences
Not applicable
168
Kochi, Mumbai, New Delhi, Ludhiana, Chandigarh, Varanasi
2025-03-15
Recruiting
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Disease on Advanced Therapies
NCT06890637Crohns Disease
All India Institute of Medical Sciences
Not applicable
168
Kochi, Mumbai, New Delhi, Ludhiana, Varanasi, Chandigarh
2025-03-15
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Guntur, Ahmedabad, Mangaluru, Mumbai, Nagpur, Nashik, Ajmer, Lucknow
2025-03-11
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Bangalore, Belagavi, Hyderabad, Kolkata, Madurai, Mumbai, New Delhi, Pune
2025-03-03
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Adrucil·Trastuzumab
AstraZeneca
Phase 3
840
Ansฤrinagar, Bangalore, Delhi, Hyderabad, Kolkata, Mumbai, Varanasi
2025-03-01
Recruiting
Effects of Advanced Trauma Life Supportยฎ on Adult Trauma Patient Outcomes
NCT06321419Wounds and Injuries
Karolinska Institutet
Not applicable
4,320
Dibrugarh, Mumbai, New Delhi, Ludhiana, Dehradun, Kolkata, Chandigarh
2025-02-27
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naรฏve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Ahmedabad, Bhubaneswar, Hyderabad, Kolkata, Mumbai, Mysuru, New Delhi, Noida
2025-02-21
Recruiting
Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial
NCT06818682Prostate Carcinoma
Tata Memorial Centre
Phase 2
206
Mumbai
2025-02-17
Recruiting
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (โ‰ฅ18 Years) Primary IgA Nephropathy?
NCT06676384IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
Christian Medical College, Vellore, India
Phase 4
585
Nadiฤd, Mysuru, Udupi, Mumbai, Delhi, Bhubaneswar, Puducherry, Chennai
2025-02-15
Recruiting
Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline
NCT06779487Brain Tumors, Medulloblastoma, Glioma, Ependymoma
Tata Memorial Centre
Observational
200
Mumbai
2025-02-11
Recruiting
Tracing Brain Tumors Through Deep Time
NCT06381531Brain Tumor, Oncology
Tata Memorial Centre
Observational
10,000
Mumbai
2025-01-10
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226Sickle Cell Disease, Thalassemia
Novo Nordisk A/S
Phase 3
480
Raipur, Mumbai, Bangalore, Gujarat, Maharashtra, New Delhi
2025-01-10
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
DrugsPF-07220060·Ribociclib·Abemaciclib·Palbociclib
Pfizer
Phase 3
1,035
Surat, Gurugram, Bangalore, Mumbai, Nashik, Pune, Thane, New Delhi
2025-01-06
Recruiting
FAPi PET in Pancreatic Ductal Adenocarcinoma
NCT07342231Pancreatic Cancer, Adenocarcinoma Pancreas
Tata Memorial Hospital
Observational
60
Mumbai
2025-01-04
Recruiting
Craniospinal Irradiation in Histone AlteRed Midline Glioma
NCT06720727Glioma
Tata Memorial Centre
Not applicable
32
Mumbai
2025-01-03
Active, closed
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
NCT06429761BREAST CANCER
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 4
100
Bangalore, Delhi, Kochi, Mumbai, New Delhi, Pune, Varanasi
2025-01-02
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Adrucil·Cetuximab
Janssen Research & Development, LLC
Phase 3
700
Delhi, Hyderabad, Kolkata, Mumbai, New Delhi, Pune, Varanasi, Vellore
2024-12-12
Active, closed
Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry
NCT07354087Endometrial Cancer
Tata Memorial Hospital
Observational
300
Mumbai, Navi Mumbai
2024-11-28
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-27
Active, closed
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742Wet Age Related Macular Degeneration, wAMD
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Ahmedabad, Kolkata, Miraj, Mumbai, Varanasi
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-18
Recruiting
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
NCT06666491Malaria, Vivax
DrugsChloroquine·Primaquine·Tafenoquine
GlaxoSmithKline
Phase 3
300
Ahmedabad, Kolkata, Mumbai, Surat
2024-11-13
Recruiting
Asian Watch-and-Wait Database (AWWD)
NCT06631443Rectal Adenocarcinoma, Rectal Cancer
Tata Memorial Centre
Observational
337
Mumbai
2024-10-22
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Erbitux·Amivantamab·Adrucil
Janssen Research & Development, LLC
Phase 3
1,000
Delhi, Kolkata, Mumbai, Pune, Varanasi
2024-10-18
Rows per page Showing 1–100 of 261
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-india/city/mumbai

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,132 studies in total at the last sync on 27 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 261 of those studies with a site in Mumbai.

How many clinical trials are recruiting in Mumbai?

148 of the 261 studies on this page are recruiting new participants as of the 27 Sep 2026, 03:16 UTC sync. A further 13 have not yet opened recruitment, 98 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Mumbai), 261 studies
PhaseStudiesRecruitingShare
Phase 31336551%
Observational362813.8%
Phase 2311511.9%
Not applicable302211.5%
Phase 2/31284.6%
Phase 41174.2%
Phase 1632.3%
Phase 1/2200.8%

Most active sponsors

Lead sponsors with the most studies (Mumbai)
Lead sponsorStudiesRecruiting
AstraZeneca3616
Tata Memorial Centre3328
Tata Memorial Hospital2216
Novo Nordisk A/S125
Bristol-Myers Squibb118
Eli Lilly and Company114
Pfizer117
Janssen Research & Development, LLC92
Novartis Pharmaceuticals86
Hoffmann-La Roche61
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.